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Antiproliferative and genotoxic potential of xanthen-3-one 
derivatives
Twelve previously synthesized, biologically active 2,6,7-tri-
hydroxyxanthen-3-one derivatives were evaluated in vitro 
for antiproliferative activity. Compounds were screened 
against HeLa, SW620, HepG2 and A549 tumor cell lines. 
Compound with the trifluormethyl group on C-4’ position 
of the phenyl ring showed the best inhibitory activity to-
wards HeLa and A549 tumor cells with IC50 of 0.7 and 4.1 
µmol L–1, resp. Compound with chlorine and fluorine sub-
stituents on aryl ring showed the best antiproliferative activ-
ity against SW620 with IC50 of 4.1 µmol L–1 and against 
HepG2 tumor cell line with IC50 of 4.2 µmol L–1. Analyses of 
cytotoxic and genotoxic potential of the trifluormethyl de-
rivative were performed with cytokinesis-block micro nu-
cleus cytome assay in human lymphocyte culture and re-
vealed no geno to xic and cytotoxic effects. The most potent 
compounds were subjected to molecular docking simu la-
tions in order to analyse bindings to molecular targets and, 
at the same time, further support the results of experimental 
cytotoxic tests. Docking studies showed sites of importance 
in forming hydrogen bonds of the most potent compounds 
with targets of interest.
Keywords: antiproliferative activity, genotoxic potential, 
docking study, xanthen-3-one derivatives, cytokinesis- 
-block micronucleus cytome assay
Xanthene derivatives are biologically active compounds with broad therapeutic ap pli-
cations that naturally occure. Some of the derivatives possess anticancer (1), antimicrobial 
(2), immunomodulating (3), antioxidant (4), anti-inflammatory (5) and other positive bio-
logical activities (6–8). One of the initial phases in the testing of the medicinal compounds’ 
potential is the examination of genotoxicity (mutagenicity) (9–11). In the last decade, in vitro 
tests on peripheral blood lymphocytes cultures have been developed to understand the 
genotoxicity. Measurement of micronuclei (MNi) in human peripheral blood lymphocytes 
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DNA damage in humans. The most reliable method for measuring MNi in PBLs is the 
cytokinesis-block micronucleus (CBMN) assay (12, 13). Nowadays, cytokinesis-block mi cro-
nucleus cytome (CBMN-cyt) assay includes the analysis of nuclear buds, nucleoplasmic 
bridges, proliferative status, apoptotic and necrotic cells in addition to micronuclei, thus, 
it is recognised as a comprehensive system for measuring DNA damage, cytostasis, and 
cytotoxicity (14). All of the above mentioned is an incentive for the synthesis of new de-
rivatives and research of their desired biological activity (like antiproliferative), as well as 
genotoxicity as an unwanted effect.
In our previous work (15, 16), we had prepared twelve 9-aryl substituted 2,6,7-tri hy-
dro xyxanthen-3-one derivatives using a reliable one-pot synthesis followed by structure 
elucidating measurements, and had performed antiplatelate and antimicrobial evaluation. 
Antiproliferative studies of similar xanthenes were reported (17–19), however, none of 
these particular derivatives have been evaluated so far. Presented study aimed to evaluate 
the antiproliferative activity of synthesized 9-aryl substituted xanthen-3-ones against 
HeLa, SW620, HepG2 and A549 tumor cell lines. The most potent compounds were sub-
jected to molecular docking simulations and genotoxic effects on peripheral blood lym-
phocytes cultures.
EXPERIMENTAL
In our previous work, we had synthesized and confirmed the structure of twelve 
xanthen-3-one derivatives 1−12 from 1,2,4-triacetoxybenzene and different aromatic alde-
hydes under acidic alcoholic conditions (15, 20, 21). Structures of the tested compounds are 
shown in Fig. 1. 
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Cell culturing for the antiproliferative evaluation
HeLa (cervical carcinoma), SW620 (colorectal adenocarcinoma, metastatic), 3T3 (mouse 
embryo fibroblast cell line), HEpG2 (liver hepatocellular cells) and A549 (adenocarcinomic 
human alveolar basal epithelial cells) cell lines were cultured as monolayers and main-
tained in Dulbecco’s modified Eagle medium (DMEM, Lonza, Austria) supplemented with 
10 % fetal bovine serum (FBS), 2 mmol L–1 L-glutamine, 100 U mL–1 penicillin and 100 µg 
mL–1 streptomycin in a humidified atmosphere with 5 % CO2 at 37 °C. Trypan blue solution 
was used to determine cell viability using an automatic cell counter (Countess, Invitrogen, 
USA). Morphology was determined under a light microscope (Axio Vision-Zeiss, Germa-
ny).
Proliferation assays
To a panel of adherent cell lines, tested compounds were added in five, 10-fold 
dilutions (0.01 to 100 µmol L–1) and incubated for 72 h. The solvent dimethylsulfoxide was 
also tested for eventual inhibitory activity. After 72 h of incubation, the cell growth rate 
was evaluated by performing the MTT assay.
Each test point was performed in quadruplicate in three individual experiments. 
Experimentally determined absorbance values (at 570 nm) were calculated into a cell 
percentage growth (PG) using the formulas proposed by NIH and described previously 
(22). The IC50 and LC50 values for each compound were calculated from dose-response 
curves using linear regression analysis.
Docking study
Lamarckian Genetic Algorithm of the AutoDock 4.0 program was used to perform the 
flexible-ligand docking studies (23). Drug target’s X-ray crystal structures obtained from 
the protein data bank (www.pdb.org) were applied in docking studies. Drug targets 
relevant in these studies were vascular endothelial growth factor 2 (VEGFR2, PDB: 1VR2), 
transforming growth factor-α (TGF-α, PDB: 4TGF), transforming growth factor β (TGF-β, 
PDB: 2TGI), and thymidylate synthase (PDB: 2TSC).
Prior to actual docking run, AutoGrid 4.0 was introduced to precalculated grid maps 
of interaction energies of various atom types. In all dockings, a grid map with 126*126*126 
points, a grid spacing of 1.000 Å was used. In an AutoGrid procedure, the protein is 
embedded in a 3D grid and a probe atom is placed at each grid point. The energy of 
interaction of this single atom with the protein is assigned to the grid point. Autodock 4.0 
uses these interaction maps to generate an ensemble of low energy conformations. It uses 
a scoring function based on the AMBER force field and estimates the free energy of binding 
of a ligand to its target. For all dockings, 10 independent runs with step sizes of 0.2 Å for 
translations and 5 Å for orientations and torsions, an initial population of random 
individuals with a population size of 150 individuals, a maximum number of 250000 
energy evaluations and 27000 maximum generations have been done.
Binding modes between ligands and target macromolecule were analyzed, visualized 
and edited by using Autodock tools program (ADT, Version 1.5.4) and PyMol-1.1 software 
(24).
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Cytokinesis-block micronucleus cytome assay
For testing of genotoxic potential in human lymphocyte culture, compound with the 
best antiproliferative activity was dissolved in DMSO and added to the culture medium to 
the final concentrations of 0.05, 0.5 and 5.0 µmol L–1. Concentrations were determined 
according to the results of MTT assay in tumour cell lines.
Healthy, non-smoking blood donor signed informed consent forms and donated 8 mL 
of peripheral blood samples for this study. Ethical Committee of the Institute for Genetic 
Engineering and Biotechnology has approved blood collection from a healthy volunteer 
for in vitro genotoxicological analysis of compounds tested in this study (Approval No: 
15-1/16 from June 15th, 2016).
Analysis of the cytotoxic and genotoxic potential was performed applying cytokinesis-
block micronucleus cytome assay (CBMN-cyt assay) in human lymphocyte culture 
according to OECD Guideline for the Testing of Chemicals (2014).
Lymphocyte cultures were set up by adding 400 µL of whole blood in 5 mL of PB-
MAX Karyotyping Medium (Life Technologies, Grand Island, NY, USA). Cultivation 
lasted 72 h at 37 °C. The tested compound was added to the cultures 24 h after cultures 
initiation in the final concentrations of 0.05, 0.5 and 5.0 µmol L–1. The same volume of 
DMSO was added to negative controls. Mitomycin C was used as a toxic agent in the 
positive control (0.25 µg mL–1). Cytokinesis blocking agent – cytochalasin B (Sigma-
Aldrich Co., USA) was added at the beginning of the 45th hour of cultivation in the final 
concentration of 4.5 µg mL–1. For each tested concentration and controls, duplicated 
cultures were used. After 72 h of cultivation, cultures were briefly treated with 0.56 % 
KCl, fixed three times in absolute ethanol/glacial acetic acid 3:1 fixative and dropped on 
the coded microscope slides. Slides were stained in 5 % Giemsa for 7 minutes.
Slides were analyzed at 400× magnification on the Olympus BX51 microscope (Tokyo, 
Japan) by two experienced scorers, according to established criteria (14, 25, 26). Genotoxic 
potential of substance was determined by analyzing frequencies of micronuclei, 
nucleoplasmic bridges, and nuclear buds in 2000 binuclear (BN) cells per each replication 
(4000 per treatment).
Frequencies of mononuclear, binuclear, trinuclear, and quadrinuclear cells, as well as 
apoptotic and necrotic cells, were scored in the total number of at least 500 counted cells 
per replicate (1000 per treatment). Cytostatic and cytotoxic effects of the tested compound 
were examined by the calculation of the nuclear division index (NDI) and nuclear division 
cytotoxicity index (NDCI), according to recommended equations (25).
Statistic analysis
Significance of differences between means of all observed genotoxicity parameters in 
treated and control cultures was analyzed using the Fisher exact test and Monte-Carlo 
permutation test. For the testing of differences between values of cytotoxicity indexes, 
two-way ANOVA was used. Statistical analyses were conducted in the PAST 3.18. (27). 
Influence of concentrations on frequencies of the observed genotoxicity and cytotoxicity 
parameters was tested by linear regression analysis using MedCalc 10.4.0.0. software.
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MTT assay was used in order to determine IC50 values (values at which 50 % of cells 
are inhibited) of the tested compounds.
Different substituents play a very important role in the activity of this series of com-
pounds. The addition of hydroxy or methoxy group to aryl ring decreases the antiprolif-
erative activity against tested tumor cells. In support of that, compounds 5 and 6 with 
methoxy and hydroxy groups on the aryl ring showed weak antiproliferative activity (> 
100 µmol L–1). Activity is improved with the addition of halogen substituents such as chlo-
rine, fluorine and bromine. Compound 12 with chlorine and fluorine substituents at the 
aryl ring (9-(2’-chloro-6’-fluorophenyl)-2,6,7-trihydroxyxanthen-3-one) showed the best 
antiproliferative activity against SW620 and HepG2 (4.2 and 4.1 µmol L–1, respectively) 
tumor cell lines, whereas compound 9 with the trifluoromethyl group on C-4’ position on 
the phenyl ring showed the best inhibitory activity towards HeLa and A549 tumor cell 
lines (0.7 and 4.1 µmol L–1, respectively).
Docking study
Docking studies were performed for the most potent synthesized compounds for indi-
vidual tumor cell lines. In docking studies for HeLa tumor cell lines, vascular endothelial 
growth factor 2 (VEGFR2, PDB: 1VR2), an important factor in tumor cell angiogenesis, was 
Table I. IC50 values of compounds 1–12 in tested cell lines
Compd.
IC50 (µmol L–1)
SW620 HEpG2 3T3 HeLa A549
1 29.1 27.2 3.9 5.3 30.9
2 49.8 35.1 6.3 8.9 52.8
3 56.8 42.7 8.9 27.5 74.1
4 21.7 16.9 0.8 4.9 32.9
5 > 100 > 100 < 0.01 > 100 > 100
6 > 100 > 100 < 0.01 36.6 > 100
7 6.8 13.1 < 0.01 2.9 37.1
8 8.8 5.8 < 0.01 5.0 39.7
9 6.1 4.8 1.7 0.7 4.1
10 91.9 59.6 > 100 40.8 > 100
11 6.6 5.1 3.4 1.5 4.3
12 4.2 4.1 1.9 4.6 6.5
SW620, A549, HepG2 and HeLa are carcinoma cell lines and 3T3 is healthy control mouse embryo fibroblast cell line.
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used as a drug target. Tyrosine kinase in VEGFR2 is on the surface of tumor cells and is 
responsible for transfosforilation and activation of antitumor drugs (28, 29).
For the most prominent xanthen-3-one derivative 9, docking studies have shown that 
it binds to the target by three hydrogen bonds: proton from OH groups in the C-2 position 
with oxygen from Arg 1080; proton from OH group at position C-7 with oxygen from Ile 
1025; oxygen from the OH group in the C-6 position with nitrogen from Ile 1025 (Fig. 2). 
The binding energy of compound 9 with the target was –4.61 kcal mol–1.
Fig. 2. The binding of compound 9 with vascular endothelial growth factor 2.
Fig. 3. The binding of compound 9 with transforming growth factor β.
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In the docking studies of the antitumor effect for lung carcinoma cells (A549), a 
transforming growth factor β (TGF-β, PDB: 2TGI) was used as the drug target, which is 
crucial in the migration processes and metastases of lung carcinoma cells (30, 31). 
Compound 9, the most potent xanthen-3-one derivative toward A549 cell line, binds to the 
target with energy of –4.61 kcal mol–1 by constructing three hydrogen bonds, via oxygen 
in the composition of the xanthene core with Cys 48 and oxygen from a carbonyl group at 
the C-3, which makes two hydrogen bonds with Cys 78 and Gly 46 (Fig. 3).
An enzyme thymidylate synthase (PDB: 2TSC) was used as a drug target for docking 
studies of antitumor effect toward HepG2 cell line, because of its importance in the 
proliferation and metastases of hepatocellular carcinoma cells (32). The best antitumor 
activity against hepatocellular carcinoma cells (HepG2) showed compound 12. Docking 
studies have shown that xanthen-3- one derivatives bind to thymidylate synthase via a 
Fig. 4. The binding of compound 12 with thymidylate synthase.
Fig. 5. The binding of compound 12 with transforming growth factor-α.
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hydrogen bond between OH group at the C-6 position with the NH group of histidine on 
the target (His 624). Compound 12 binds to the target with the energy of –6.36 kcal mol–1.
As a drug target in docking studies of synthesized xanthene compounds against 
colorectal carcinoma cells (SW620), a transforming growth factor-α (TGF-α, PDB: 4TGF) 
was used. The transforming growth factor is important for the proliferation of the SW620 
cells (33). The best antiproliferative activity against the SW620 cell line showed compound 
12, which binds with the target by forming six hydrogen bonds with the target. Oxygens 
from C-2 and C-3 form three bonds with Cys 919, and O-10 and oxygen from C-6 form three 
bonds with Gly 841 (Fig. 5). The binding energy of compound 12 with the target was –6.07 
kcal mol–1.
The obtained results of the docking studies could be the basis for discovering the 
mechanism of action for synthesized xanthene compounds, in conjunction with additional 
in vitro tests.
Genotoxicity
Genotoxicity of compound 9 (the most potent antiproliferative compound) was 
evaluated in cytokinesis blocked human lymphocytes by scoring micronuclei (MNi), 
Table II. Results of cytostatic and cytotoxic activity of compound 9 in cultures of human lymphocytes




1 329 161 13 34 537 5 0 542 1.54 1.53
2 397 174 14 25 610 4 2 616 1.45 1.45
Xav 363 167.5 13.5 29.5 573.5 4,5 1 579 1.50 1.49
0.05 µmol L–1
1 355 168 11 25 559 5 1 565 1.47 1.47
2 312 160 13 23 508 5 0 513 1.50 1.50
Xav 333.5 164 12 24 533.5 5 0,5 539 1.49 1.48
0.5 µmol L–1
1 351 137 8 22 518 6 0 524 1.42 1.42
2 391 135 14 13 553 5 1 559 1.37 1.36
Xav 371 136 11 17.5 535.5 5.5 0.5 541.5 1.39 1.39
5 µmol L–1
1 353 139 9 15 516 8 1 525 1.39 1.39
2 352 136 16 27 531 5 3 539 1.47 1.46
Xav 352.5 137.5 12.5 21 523.5 6.5 2 532 1.43 1.42
Positive 
control mytC
1 448 79 2 2 531 8 1 540 1.17 1.17
2 416 113 1 2 532 14 3 549 1.23 1.22
Xav 432 96 1.5 2 531.5 11 2 544.5 1.20 1.19
M1-M4 – cells with 1–4 nuclei; N – number of total scored cells; Ap – apoptotic cells; Nec – necrotic cells; NDI – 
nuclear division index; NDCI – nuclear division and cytotoxicity index.
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nuclear buds (NBUDs) and nucleoplasmic bridges (NPBs) in a total of 4000 binuclear cells 
(BN) per treatment (2000 per each replicate). Cytostatic and cytotoxic effects, expressed as 
nuclear division indexes (NDI and NDCI), were calculated after scoring of mono-, bi-, tri- 
and tetranuclear cells as well as apoptosis and necrosis in at least 500 cells per replication 
(1000 cells per treatment). Results of the analysis are presented in Table II.
The statistical analysis revealed no significant differences between frequencies of mi-
cronuclei and nuclear buds in the treated and negative control cultures, whereas a signifi-
cant increase of these parameters was evidenced in the positive control (p < 0.05). The 
frequencies of nucleoplasmic bridges in controls and treatments did not significantly dif-
fer. Linear association between logarithmic values of compound 9 concentrations and fre-
quencies of all observed parameters revealed no significant relationship (p > 0.05).
Two-way ANOVA for two replicates showed no significance between calculated val-
ues of nuclear division indexes in treatments and negative control, while NDI and NDCI 
in the positive control were significantly lower than that of the negative control and 0.05 
µmol L–1 treatment (Table III). No linear association between concentration and cytotoxic-
ity indexes was observed.
As used in the food and drug industry, xanthene dyes were extensively studied to 
analyse their genotoxic potential. Numerous studies confirmed that certain xanthenes (e.g. 
erythrosine) induce DNA damage and should be carefully consumed (34). In the study 
performed by Eisenträger et al. (35) quinoline, 6-methylquinoline and xanthene caused 
mutagenic effects in the Ames assay with Salmonella typhimurium only after the metabolic 
activation. However, the conducted analysis of compound 9 has not revealed its genotoxic 
potential in the tested concentrations.
CONCLUSIONS
Majority of tested xanthen-3-on derivatives exerted antiproliferative effects on tumor 
cell lines. Compound 12, with chlorine and fluorine substituents at the aryl ring, showed 
the best antiproliferative activity against SW620 with IC50 of 4.1 µmol L–1 and against 
HepG2 tumor cells line with IC50 of 4.2 µmol L–1. Towards HeLa and A549 tumor cells, the 
Table III. Means of observed genotoxicity and cytotoxicity parameters in cytokinesis-blocked lymphocytes
Treatments
Xav/1000 BN cells Xav/500 cells
MNi NBUDs NPBs NDI NDCI
Negative control (DMSO) 6.25a 2.5a 0 1.50a 1.49a
0.05 µmol L–1 5.5a 2a 0 1.49a 1.48a
0.5 µmol L–1 4.75a 0.5a 0.25 1.39 1.39
5 µmol L–1 9.75a 1.75a 0 1.43 1.42
Positive control (mytC) 101.25 8.75 1.5 1.20 1.19
a Significantly different against the positive control
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best inhibitory activity showed compound 9 with the trifluormethyl group at C-4’ position 
on the phenyl ring with IC50 of 0.7 µmol L–1 against HeLa and IC50 of 4.1 µmol L–1 against 
A549 tumor cell lines. Docking studies, carried out on vascular endothelial growth factor 
2 (VEGFR2), thymidylate synthase, transforming growth factor β (TGF-β) and transforming 
growth factor-α (TGF-α) as drug targets, showed sites of importance in forming hydrogen 
bonds with targets for the most potent compounds. The performed analyses revealed no 
genotoxic and cytotoxic effects of compound 9 (the most potent antiproliferative com-
pound) in concentrations of 0.05, 0.5 and 5 µmol L–1, thus, this compound should be the 
subject of further research and potential applications.
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